Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study.

Luca AreccoMaria Maddalena LatoccaEva BlondeauxFerdinando RiccardiCarmela MocerinoValentina GuarneriEleonora MioranzaGiancarlo BisagniElisa GaspariniFabio PuglisiAlexandro MembrinoAntonella FerroVincenzo AdamoFilippo GiovanardiStefano TamberiSara DonatiElisabetta LanducciLaura BiganzoliSara PiccininiSimona PastorinoEvandro de AzambujaFrancesca PoggioMatteo LambertiniLucia Del Mastro

Published in: Breast (Edinburgh, Scotland) (2024)

AI with OFS is the most prescribed adjuvant ET among premenopausal patients, especially in the presence of high-risk features.

Keyphrases

early breast cancer
end stage renal disease
early stage
ejection fraction
postmenopausal women
newly diagnosed
chronic kidney disease
artificial intelligence
stem cells
machine learning
patient reported outcomes
mesenchymal stem cells